Vidaza Umoja wa Ulaya - Kroeshia - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

BISOLVON 2mg/ml Oralni rastvor/koncentrat za rastvor za raspršivanje Montenegro - Kroeshia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

bisolvon 2mg/ml oralni rastvor/koncentrat za rastvor za raspršivanje

dio stranog druŠtva "sanofi - aventis" - podgorica - bromheksin - oralni rastvor/koncentrat za rastvor za raspršivanje - 2mg/ml

BISOLVON 8mg Tableta Montenegro - Kroeshia - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

bisolvon 8mg tableta

dio stranog druŠtva "sanofi - aventis" - podgorica - bromheksin - tableta - 8mg